RGD-AAVP-TNF therapy (PhageNova Bio)

N/A

Report date: 2025/06/11 10:48:11

Base Information

Drug NameRGD-AAVP-TNF therapy (PhageNova Bio)
Drug Alias NameRGD-AAVP-TNF therapy (AAVP Biosystems)adeno-associated virus bacteriophage tumor necrosis factor therapy (AAVP Biosystems)oncolytic adeno-associated virus/bacteriophage therapy expressing TNF-alpha (PhageNova Bio)AAVP-001RGD-A-TNF
ClassificationBiologics > BacteriophagesBiologics > Oncolytic virus
Mechanisms of ActionIntegrin alpha-V/beta-3 modulatorsTumor necrosis factor receptor agonistsImmunostimulants
TargetsTumor necrosis factor receptorIntegrin alpha-V/beta-3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesPhageNova Bio Inc
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A